
U.S. again puts India on 'priority watch list' for alleged IP rights' violations
The U.S. on Tuesday (April 29, 2025) once again placed India on its 'priority watch list', stating that New Delhi remains one of the world's most challenging major economies for the protection and enforcement of intellectual property rights (IPRs).
The U.S. Trade Representative's (USTR) 2025 Special 301 report, an annual review of the global state of IPR protection and enforcement, said that over the past year, India has remained inconsistent in its progress on intellectual property protection and enforcement.
It said that although India has worked to strengthen its IP regime, including raising public awareness about the importance of the subject, and engagement with the U.S. on IP issues has increased, there continues to be a lack of progress on many long-standing IP concerns.
"India remains one of the world's most challenging major economies with respect to protection and enforcement of IP... India remains on the Priority Watch List in 2025," it said.
The country had earlier stated that this report is a unilateral measure taken by the U.S. under their Trade Act, 1974 to create pressure on countries to increase IPR protection beyond the TRIPS agreement. Besides, India has maintained that its IPR regime is fully compliant with global trade norms.
The report comes in the backdrop of India-U.S. negotiating a bilateral trade agreement to boost two-way commerce to $500 billion by 2030. The U.S. is looking at bridging its trade deficit with India, which was $41.18 billion in 2024-25, through this pact.
A trade expert said India has a well established legislative, administrative and judicial framework to safeguard IPR that meets its obligations under the WTO's Agreement on Trade Related IPRs (TRIPS).
The concerns identified in the report are based on the inputs provided by the American industry on their perception of the level of protection provided by India to Intellectual Property.
The report also said patent issues continue to be of particular concern in India.
"Among other concerns, the potential threat of patent revocations and the procedural and discretionary invocation of patentability criteria under the Indian Patents Act impact companies across different sectors. Moreover, patent applicants generally continue to confront long waiting periods to receive patent grants and excessive reporting requirements," the report said.
Stakeholders continue to express concerns over vagueness in the interpretation of the Indian Patents Act, it alleged.
It added that India maintains high customs duties directed to IP-intensive products such as information and communications technology products, solar energy equipment, medical devices, pharmaceuticals, and capital goods.
"While steps to improve IP Office operations and procedures are to be commended, India's overall IP enforcement remains inadequate," it said.
It added that the US intends to continue to engage with India on IP matters, including through the trade policy forum's intellectual property working group.
The report has listed eight countries, including India in its 'priority watch list'. China, Indonesia, Russia, Argentina, and Venezuela are among others on the list.
It has also placed 25 countries, including Pakistan and Turkey, on the list.
U.S. Trade Representative (USTR) Jamieson Greer said the USA's trading partners must address the concerns identified in the report and stop those stealing the intellectual property of hard-working businesses and individuals.
This annual report details USTR's findings of more than 100 trading partners after research and engagement with stakeholders.
Other issues that have been flagged in the report include, concerns over the provision of Section 3(d) of the Patent Act, and pharmaceutical patent disputes.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

The Hindu
8 hours ago
- The Hindu
Will manufacture and export but not sell weight-loss drug in India, Dr. Reddy's tells Delhi HC
Dr. Reddy's Laboratories Ltd. and OneSource Specialty Pharma have given an undertaking before the Delhi High Court that they will neither sell nor market Novo Nordisk's anti-obesity drug Wegovy within India pending the outcome of a patent infringement lawsuit filed by the Danish pharmaceutical giant. The case concerns an alleged violation of Novo Nordisk's patent on its diabetes medication, semaglutide. Dr. Reddy's and OneSource, represented by senior advocates Abhishek Manu Singhvi and Mukul Rohatgi, respectively, informed the court that while Dr. Reddy's has been granted a licence to manufacture the contested drug in December 2024 and began production in April 2025, Dr. Reddy's currently does not hold a licence to sell the drug in India. Dr. Reddy's and OneSource gave an assurance that they will will not sell the drug in India. However, the Indian parma companies said they reserve their right to export the drug in countries where Novo Nordisk has not been granted a patent yet. These submissions were formally taken on record by the court, and the counsel for two pharma companies confirmed that the undertaking would remain binding on the company until the next hearing. Appearing for Novo Nordisk, senior advocate Sandeep Sethi argued that under the Indian Patents Act, 1970, even exporting a product that infringes a patent constitutes an act of infringement. The court, in its May 29 order, said it will consider the submission of the parties on the next date of hearing, on August 19.


Hindustan Times
3 days ago
- Hindustan Times
Democrat Warren raises concerns that US tariff deals will favor Big Tech over workers
-Democratic U.S. Senator Elizabeth Warren on Wednesday expressed concern the Trump administration's tariff negotiations would favor big technology firms at the expense of consumers and workers. In a letter to U.S. Trade Representative Jamieson Greer, Commerce Secretary Howard Lutnick and Treasury Secretary Scott Bessent, Warren said Big Tech has long sought to use trade negotiations to "undermine pro-consumer, pro-competition policies." She asked for details on the officials' interactions with tech industry executives. WHY IT'S IMPORTANT Warren has for years argued in favor of stronger regulation on big technology firms. President Donald Trump has taken a stance favorable to the technology sector, taking aim at foreign governments' regulatory restrictions and digital services taxes aimed at capturing revenue from Meta, Apple, Alphabet's Google, Amazon and other U.S. tech firms. Trump in February ordered a revival of tariff retaliation probes over digital services taxes, and Greer and Bessent have raised U.S. opposition to digital services taxes as part of trade negotiations. In her letter, Warren said she was concerned by a list of 10 digital trade grievances against U.S. trading partners posted by USTR on X, including the European Union's Digital Services Act and Digital Markets Act and South Korea's cross-border data flow restrictions. KEY QUOTE: Warren said that given the industry's large donations, presence at Trump's inauguration and its success in lobbying for temporary tariff exemptions, "I am gravely concerned renegotiated trade deals will be used to advance Big Tech's anti-consumer agenda while doing nothing to promote U.S. manufacturing or help American workers." Spokespersons for USTR, the Treasury and the Commerce Department did not immediately respond to a request for comment.


Indian Express
5 days ago
- Indian Express
India-US trade deal talks: US team to visit India in June; Goyal to meet export promotion councils Tuesday
India's trade negotiations with the US is entering the final leg, with Commerce Minister Piyush Goyal set to meet members of export promotion councils (EPCs) on Tuesday, and the US trade team likely to arrive in India next month for talks as New Delhi aim to wrap up negotiations by the end of the 90-day reciprocal tariffs pause, which ends on July 9, The Indian Express has learnt. The consultation meeting with EPCs is scheduled after Goyal led the Indian delegation to Washington last week, where he met US Commerce Secretary Howard Lutnick to advance trade talks. India is seeking the elimination of the 26 per cent reciprocal tariff and duty-free entry for labour-intensive export items such as textiles and footwear in the US. Indian goods currently attract a 10 per cent baseline US tariff which could continue even after the trade deal comes into effect. India and the US had earlier decided to conclude the first phase of the proposed bilateral trade agreement by the autumn (September–October) of this year. However, both sides have now agreed on an interim trade deal before the first tranche, to be finalised by July 9. The interim deal is expected to cover a limited range of goods and services, with the US seeking market access in India for items including agricultural products. However, US President Donald Trump has continued his tariff rhetoric targeting India. After Apple announced that a majority of iPhones to be sold in the US would be produced in India, Trump said on Friday that Apple would have to pay a 25 per cent tariff if it sold iPhones in the US that are built in India or elsewhere. Trump also stated that he had told Apple CEO Tim Cook he does not want the company to expand its manufacturing operations in India unless it is to serve the Indian domestic market. Moreover, an April report by the Office of the United States Trade Representative (USTR) criticised various Indian trade barriers, including 'localised internet shutdowns that disrupt commercial operations' and regulations requiring that 'dairy products intended for food must be derived from animals that have not consumed feed containing blood meal'. 'India requires that dairy products intended for food be derived from animals that have not consumed feed containing internal organs, blood meal, or tissues of ruminant or porcine origin, and that exporting countries certify to these conditions, which lack a discernible animal health or human health justification,' the report said. Highlighting possible US demands in the ongoing negotiations, the report flagged India's regulations on the import of milk, pork, and fish products, stating that they require genetically modified (GM)-free certificates 'without providing a scientific or risk-based justification'. Indicating that Washington fears another China in the making, the report said the US has placed India on the 'Priority Watch List' due to inconsistent progress on intellectual property (IP) concerns. It highlighted the absence of specific laws for trade secret protection as a significant issue, alongside long waiting periods for patent grants. The US remained India's largest trading partner for the fourth consecutive year in 2024–25, with bilateral trade valued at $131.84 billion. The US accounts for about 18 per cent of India's total goods exports, 6.22 per cent of imports, and 10.73 per cent of the country's total merchandise trade. With the US, India had a trade surplus (the difference between exports and imports) of $41.18 billion in goods in 2024–25. It was $35.32 billion in 2023–24, $27.7 billion in 2022–23, $32.85 billion in 2021–22, and $22.73 billion in 2020–21. Ravi Dutta Mishra is a Principal Correspondent with The Indian Express, covering policy issues related to trade, commerce, and banking. He has over five years of experience and has previously worked with Mint, CNBC-TV18, and other news outlets. ... Read More